We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01006239
Previous Study | Return to List | Next Study

The Biorepository for Scripps Health (BIF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01006239
Recruitment Status : Active, not recruiting
First Posted : November 1, 2009
Last Update Posted : March 17, 2021
Information provided by (Responsible Party):
Eric Topol, MD, Scripps Translational Science Institute

Brief Summary:

The investigators propose to establish a Biorepository of both diseased and normal tissue collected from subjects undergoing surgery for solid tumor resection. In cooperation with the Scripps Cancer registry, the investigators will also establish an anonymized database of corresponding clinical information including response to treatment, disease status, and recurrence.

The Biorepository for Scripps Health will be able to process, preserve, and distribute samples to scientific and medical researchers at Scripps.

Condition or disease Intervention/treatment
Cancer Other: No study intervention

Detailed Description:

Biorepository samples will be utilized in a variety of research studies intended to help in the diagnosis and/or treatment of patients, including the possible identification of therapeutic targets or genetic identifiers of cancers and possibly other diseases. Various technologies including gene expression, genotyping, DNA and RNA sequencing, protein and metabolite analysis may be used in the course of the various studies An exemplary project currently under consideration is one in which Scripps Genomic Medicine is comparing the DNA sequence of both a patient's tumor and their germline DNA to identify genetic differences between the two. These differences could help identify specific pathways that are regulating the tumor and disease thus leading to potentially valuable information in how to treat that individual patient as well as other patients with similar genetic characteristics. In addition, differences between the tumor and germ-line observed in multiple patients could help identify therapeutic targets that are cancer specific. A secondary exemplary project which is currently underway is one in which Scripps Genomic Medicine is undertaking RNA sequencing to identify "fusion genes" which are hybrid genes formed from two previously separate genes and are a type of genetic mutation that has been identified in certain types of cancers including those of the prostate and breast and certain forms of leukemia. Identifying new fusion genes could provide valuable insights into both treatment protocols and new therapeutic targets.

The goal of this project is to expand and improve the bio-repository already established within the Scripps Genomic Medicine (SGM) group. Presently, the collection has been focused on the collection of predominately prostate tumors and blood as the corresponding normal tissue. The current collection is annotated with pathology information and limited medical information collected from the patient during the consenting process; no post surgical information is collected. We believe that collection can be enhanced by (i) modifying the tumor collection process, (ii) simplifying the means of consenting the patients such that it relies upon the general surgical consent and (iii) using de-identified medical data already consolidated in the Cancer registry as a means of annotating the tissue samples.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 10000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Biorepository for Scripps Health
Study Start Date : November 2009
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : January 2023

Group/Cohort Intervention/treatment
Patients undergoing surgical resection of a solid tumor.
Other: No study intervention
The is no study related intervention.

Primary Outcome Measures :
  1. Establish a Biorepository of both diseased and normal tissue [ Time Frame: six years ]
    Establish a Biorepository of both diseased and normal tissue

Biospecimen Retention:   Samples With DNA
We will be collecting solid tumor and adjacent non-diseased tissue from patients undergoing surgical resection of a solid tumor.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects over the age of 18 undergoing surgical resection of solid tumor.

Inclusion Criteria:

  • Age 18 or older
  • Undergoing surgical resection of solid tumor
  • Completion of general surgical consent (authorizing "pathologist to use his or her discretion in the disposition or use of any tissues removed during surgery or other procedure unless otherwise directed by my physician. I understand that tissues that are removed may be used for teaching purposes as well as research, institutional or commercial".)

Exclusion Criteria:

  • Does not meet all of the inclusion criteria above.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01006239

Layout table for location information
United States, California
Scripps Mercy Hospital
San Diego, California, United States, 92103
Sponsors and Collaborators
Scripps Translational Science Institute
Layout table for investigator information
Principal Investigator: Eric J Topol, MD Scripps Translational Science Institute and Genomic Medicine
Layout table for additonal information
Responsible Party: Eric Topol, MD, Director, Scripps Translational Science Institute, Scripps Translational Science Institute
ClinicalTrials.gov Identifier: NCT01006239    
Other Study ID Numbers: IRB 09-5261
First Posted: November 1, 2009    Key Record Dates
Last Update Posted: March 17, 2021
Last Verified: March 2021
Keywords provided by Eric Topol, MD, Scripps Translational Science Institute: